petri dish

Helping Imperial's academics successfully lead large, collaborative research initiatives.

Horizon 2020

Horizon 2020 is the biggest EU Research and Innovation programme ever, with nearly €80 billion of funding available for multi-national collaboration projects and individual researchers, as well as SMEs.

We are currently involved in six Horizon 2020 research projects - four with teams in the Faculty of Medicine, one with the Faculty of Engineering - and one with the KIOS Research and Innovation Center of Excellence, University of Cyprus.

Horizon 2020 projects

EAVI 2020

eavi2020 logo

EAVI2020 is a €22.9 million initiative to accelerate the search for an effective HIV vaccine - running from 2015 to 2020.

The EAVI2020 consortium, which is led by Prof Robin Shattock from Imperial College London, brings together leading HIV researchers from public organisations and biotech companies from across Europe, Australia, Canada and the USA, pooling their knowledge and expertise to develop novel candidate vaccines that can be taken through to human trials within five years. EAVI2020 is funded with an EU-grant under the health program of Horizon 2020 for research and innovation.

The Research Project Management team provide consortium management to the 22 partner institutions and leads on the project’s dissemination, communication and impact activities.

To keep up to date with EAVI2020, you can visit the project's website, and follow EAVI2020 on Twitter, Facebook and LinkedIn.


EDEN 2020

EDEN 2020 logo

The Enhanced Delivery Ecosystem for Neurosurgery (EDEN2020) is an €8.3 million project (2016-2020) funded by the European Union Horizon2020 programme, which aims to translate the latest surgical robotic technologies into patient-specific neurosurgical applications, meeting the demand for better and less invasive treatment in neurosurgery. The EDEN2020 consortium was awarded this competitive Research and Innovation Action (RIA) on robotic-assisted neurosurgical drug delivery in April 2016.

The Imperial team, headed by Prof. Rodriguez y Baena, coordinates EDEN2020, which also benefits from strong industrial presence (Renishaw plc. and XoGraph ltd.), a first class clinical team in Italy (Universita’ di Milano, San Raffaele and Politecnico di Milano) led by Prof. Lorenzo Bello, and the involvement of leading experts in intra-operative imaging (Technical University of Munich) and shape sensing (Universitair Medisch Centrum Groningen).

The Research Project Management team provides consortium management to the 8 industrial and academic partners from the UK, Italy, the Netherlands and Germany. We also lead dissemination, communication and exploitation activities.

To stay up to date with the project, visit the EDEN2020 website and follow EDEN2020's Twitter, Facebook page and LinkedIn.


How it Works

DIAMONDS

Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis

DIAMONDS is a €22.5 million collaborative project (2020-2024) funded under the European Commission’s Horizon 2020 programme for research and innovation.

The 5-year project aims to develop a rapid test to diagnose severe illnesses using personalised gene signatures. It will address the challenge of bringing personalised medicine into routine use in EU healthcare systems for diagnosis and treatment of common infectious and inflammatory diseases, like pneumonia, tuberculosis, sepsis, meningitis, which account for a up to a third of all medical encounters in primary care and hospital. The scientists have called this new approach Personalised Molecular Signature Diagnosis (PMSD) and they aim to conduct the first pilot trials in UK and European hospitals in 2023 and 2024. The work builds on over a decade of research (ILULU, EUCLIDS, PERFORM) into the pattern of genes switched on in the blood in different conditions. 

The project is led by Professor Michael Levin from Imperial College and involves 27 other partners in 11 EU countries, and biotechnology groups in academia, SMEs and industry. The Research Project Management team is providing overall consortium management.

To keep up to date with DIAMONDS, follow the project on Twitter.


PERFORM

PerFORM

Personalised Risk assessment in febrile illness to Optimise Real-life Management across the European Union

PERFORM is a €17.9 million collaborative project (2016-2020) funded under the European Commission’s Horizon 2020 programme for research and innovation.

The project is looking at ways to reduce antibiotic misuse, through the development of improved tests used to distinguish bacterial from viral infections. Currently, doctors have very limited capacity to reliably differentiate life-threatening bacterial infections from trivial viral illnesses in children. As a result, thousands of children worldwide undergo investigations such as lumbar punctures, x-rays and blood cultures, and are treated with broad spectrum antibiotics while waiting to rule out bacterial infection.

The project is led by Professor Michael Levin from Imperial College and involves partners in Oxford, Liverpool, Spain, Austria, Germany, the Netherlands, Greece, Slovenia, Latvia and Switzerland, along with two biotechnology companies (Micropathology Ltd in the UK and bioMérieux in France). The Research Project Management team is providing overall consortium management, as well as dissemination and stakeholder engagement.

More information can be found on the PERFORM2020 website. Stay up to date with PERFORM and follow the project's activities on Twitter

Prof. Michael Levin says...

“Better tests to identify those children with life-threatening infection amongst the infinitely more numerous children with viral infections are urgently needed if antibiotic use is to be reduced. We have exciting pilot data which shows that bacterial infection can be recognised by the patterns of genes and proteins switched on in each child’s blood during infection. PERFORM will apply sophisticated genomic and proteomic methods to study thousands of febrile children with the aim of identifying and developing a better test for bacterial infection than what is currently available.”


PRESTIGE-AF

PRESTIGE AF logoPREvention of Stroke in Intracerebral hermorrhaGE survivor with Atrial Fibrillation

PRESTIGE-AF is a €6.9 million European Commission funded project (2017-2022) that brings together scientists and clinicians across Europe to reduce the risk of Stroke in patients.

PRESTIGE-AF addresses the unmet need of best antithrombotic stroke prevention in Intracerebral haemorrhage (ICH) patients with atrial fibrillation (AF). Recurrent stroke reduces individual life expectancy, quality of life and has high public health impact. The project’s consortium will generate new tools to tailor prevention.

The project is led by Professor Roland Veltkamp from the Department of Medicine at Imperial College London and involves 11 other partner institutions throughout the UK and across Europe including Denmark, Germany and France. The consortium members will work collaboratively within the European Commission framework to deliver the desired outcomes over 5 years.

The Research Project Management team is providing the Consortium Management for the project as well as dissemination, communication and exploitation management.

To keep up to date, visit the PRESTIGE-AF website and follow PRESTIGE-AF on Twitter.


 

 

KIOS Teaming Project

kios logoThe KIOS Teaming Project is a collaborative initiative funded by the European Commission’s Teaming Programme. The project is led by the KIOS Research and Innovation Centre of Excellence based at the University of Cyprus in collaboration with Imperial College London.

The mission of the KIOS Research and Innovation Centre of Excellence is to conduct multidisciplinary research and innovation in the area of Information and Communication Technologies (ICT) with emphasis on the Monitoring, Control, Security and Management of Critical Infrastructures, which include large-scale, complex systems such as power and energy systems, water systems, transportation systems, telecommunication networks and emergency management and response systems. The total value of the European Commission award is €15million and the project will run from 2017 to 2024.

The Imperial team is led by Professor Thomas Parisini from the Department of Electrical and Electronic Engineering and provides academic expertise in cyber-security and power and control systems. The Research Project Management team is providing expertise on dissemination, exploitation and communication activities, innovation management, data management and organisational transformation.

Stay up-to-date with KIOS CoE, visit the KIOS CoE website and follow the KIOS CoE Twitter.


 

EIT Climate KIC

The European Institute of Innovation and Technology (EIT) Climate-KIC is a knowledge innovation community established and funded by the EIT in 2010. Their purpose is to tackle climate change through innovation. They are Europe’s largest public-private partnership with this purpose – a growing pan-European community of diverse organisations united by a commitment to direct the power of creativity and human ingenuity at the climate change challenge.

EIT Climate KIC projects

ARISE

ARISE logo

Agriculture Resilience, Inclusive, and Sustainable Enterprise (ARISE) is a €5.4 milliom project, with €3.3 million funded by EIT Climate-KIC research project. It is running from 2019-2021 and led by Dr Enrico Biffis of the Brevan Howard Centre for Financial Analysis from Imperial College Business School.

Imagine having a set of financial incentives that can be combined and deployed to drive farmers towards the adoption of more resilient and sustainable practices. This could increase the total agricultural output in Africa and Europe, while at the same time driving the whole sector toward sustainability and climate resilience. This is exactly what we aim to achieve with the ARISE demonstrator project. WINnERS developed a financial de-risking instrument, where the cost of insurance depends on basic farming practices improvements such as better seeds or fertilizers. The project has high ambitions and our intention is to leverage the successful innovation already brought to market with the WINnERS demonstrator.